Media stories about Intermolecular (NASDAQ:IMI) have been trending somewhat positive this week, Accern reports. The research group identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Intermolecular earned a daily sentiment score of 0.14 on Accern’s scale. Accern also assigned media coverage about the semiconductor company an impact score of 45.8724542362731 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Separately, ValuEngine upgraded Intermolecular from a “sell” rating to a “hold” rating in a research note on Sunday, December 31st.
Intermolecular (NASDAQ:IMI) traded up $0.03 during trading hours on Wednesday, reaching $1.48. The company had a trading volume of 700 shares, compared to its average volume of 67,588. The stock has a market cap of $73.35, a P/E ratio of -7.05 and a beta of 1.16. Intermolecular has a 12-month low of $0.80 and a 12-month high of $1.65.
TRADEMARK VIOLATION NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect Intermolecular (IMI) Stock Price” was published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://www.tickerreport.com/banking-finance/3228450/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-intermolecular-imi-stock-price.html.
Intermolecular, Inc provides thin film solutions. The Company’s high productivity combinatorial (HPC) platform, which consists of its tempus processing tools, its automated characterization methods, and its Informatics analysis software, is purpose-built for research and development (R&D) using combinatorial process systems.
Receive News & Ratings for Intermolecular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intermolecular and related companies with MarketBeat.com's FREE daily email newsletter.